Over 12 months, Cullinan Therapeutics, Inc. saw more buying than selling from its insiders — purchases of about $3.5 million against sales of $2.5 million.
Biggest single buyer: Nichols Weston, 10% Owner, with roughly $1.4 million.
Zooming out by quarter: 3 quarters in a row of net selling by insiders. Insiders bought in 1 of the last 7 full quarters. 184 investment managers listed CGEM in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Michaelson Jennifer | Executive Officer | Sell | 8,000 | $21.57 | $173K | SEC |
| Aug 14, 2026 | Michaelson Jennifer | Executive Officer | Sell | 30,000 | $20.26 | $608K | SEC |
| Jul 7, 2026 | Michaelson Jennifer | Executive Officer | Sell | 8,000 | $17.82 | $143K | SEC |
| May 6, 2026 | Michaelson Jennifer | Executive Officer | Sell | 200 | $15.58 | $3K | SEC |
| May 6, 2026 | Michaelson Jennifer | Executive Officer | Sell | 7,800 | $14.60 | $114K | SEC |
| Mar 9, 2026 | Michaelson Jennifer | Executive Officer | Sell | 8,000 | $15.68 | $125K | SEC |
| Feb 26, 2026 | Michaelson Jennifer | Executive Officer | Sell | 1,780 | $14.14 | $25K | SEC |
| Feb 25, 2026 | Michaelson Jennifer | Executive Officer | Sell | 3,601 | $14.47 | $52K | SEC |
| Feb 25, 2026 | Michaelson Jennifer | Executive Officer | Sell | 1,752 | $13.99 | $25K | SEC |
| Feb 25, 2026 | AHMED NADIM | CEO | Sell | 13,515 | $14.47 | $196K | SEC |
| Feb 25, 2026 | Jones Jeffrey Alan | Executive Officer | Sell | 4,582 | $14.47 | $66K | SEC |
| Feb 25, 2026 | SUMER JACQUELYN L | Executive Officer | Sell | 3,601 | $14.47 | $52K | SEC |
| Feb 23, 2026 | Fenton Mary Kay | CFO | Sell | 4,398 | $13.62 | $60K | SEC |
| Feb 23, 2026 | Jones Jeffrey Alan | Executive Officer | Sell | 4,982 | $13.62 | $68K | SEC |
| Feb 23, 2026 | Michaelson Jennifer | Executive Officer | Sell | 8,000 | $14.30 | $114K | SEC |
In the last 12 months Cullinan Therapeutics, Inc. insiders made open-market purchases worth about $3.5 million and sales worth about $2.5 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CGEM was filed on 2026-09-10.
184 investment managers reported holding CGEM in SEC Form 13F filings for Q2 2026.
No congressional trades in CGEM were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).